PDL BIOPHARMA, INC. Business Finance Contracts & Agreements
65 Contracts & Agreements
- Credit Agreements (10 contracts)
- Exchange Agreements (7)
- Indenture Agreements (12)
- Investment Agreements (2)
- Note Agreements (3)
- Purchase Agreements (6)
- Registration Rights Agreements (2)
- Share Agreements (1)
- Stock Agreements (18)
- Underwriting Agreements (4)
- Capital Provision Agreement dated as of December 11, 2020 between the Company and Epps Investments LLC (Filed With SEC on March 29, 2021)
- Share Purchase Agreement between Bartleby Limited and the Company, dated as of July 30, 2020 (Filed With SEC on August 10, 2020)
- Form of Inducement Restricted Stock Agreement (Amended 11/15/19) (Filed With SEC on March 11, 2020)
- Form of Nonstatutory Inducement Stock Option Grant Notice Supplement (Filed With SEC on March 11, 2020)
- Form of Nonstatutory Inducement Stock Option Agreement (Amended 11/15/19) (Filed With SEC on March 11, 2020)
- Form of Stock Option Grant Notice Supplement (Filed With SEC on March 11, 2020)
- Form of Stock Option Agreement Amendment Acknowledgment (Filed With SEC on March 11, 2020)
- Form of Stock Option Agreement (Amended 11/15/19) (Filed With SEC on March 11, 2020)
- Form of Restricted Stock Agreement Amendment Acknowledgment (Filed With SEC on March 11, 2020)
- Form of Restricted Stock Agreement (Amended 11/15/19) (Filed With SEC on March 11, 2020)
- Supplemental Indenture, dated September 17, 2019 by and between PDL BioPharma, Inc., as Issuer and The Bank of New York Mellon Trust Company, N.A., as Trustee (Filed With SEC on September 17, 2019)
- Indenture, dated September 17, 2019, between PDL, BioPharma, Inc., as Issuer and The Bank of New York Mellon Trust Company, N.A., as Trustee (Filed With SEC on September 17, 2019)
- Form of Exchange Agreement (Filed With SEC on September 13, 2019)
- Securities Purchase Agreement (Filed With SEC on April 11, 2019)
- Amendment No. 1 to Royalty Purchase and Sale Agreement and Bill of Sale between PDL Investment Holding, LLC and Depomed, Inc. and Depo DR Sub, LLC, dated August 2, 2018 (Filed With SEC on August 9, 2018)
- Schedule of Amendment to Omitted Credit Agreements (Filed With SEC on March 1, 2017)
- PDL BIOPHARMA, INC. 2.75% Convertible Senior Note due 2021 (Filed With SEC on November 28, 2016)
- PDL BIOPHARMA, INC. as Issuer AND THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A. as Trustee SUPPLEMENTAL INDENTURE Dated as of November22, 2016 2.75% Convertible Senior Notes due... (Filed With SEC on November 28, 2016)
- PDL BIOPHARMA, INC. Debt Securities Indenture Dated as of November 22, 2016 The Bank of New York Mellon Trust Company, N.A., as Trustee CROSS-REFERENCE TABLE This Cross-Reference... (Filed With SEC on November 28, 2016)
- PDL BIOPHARMA, INC. (a Delaware corporation) $150,000,000 2.75% Convertible Senior Notes Due 2021 UNDERWRITING AGREEMENT Dated: November 16, 2016 PDL BIOPHARMA, INC. (a Delaware... (Filed With SEC on November 22, 2016)
- PDL BIOPHARMA, INC. (a Delaware corporation) $150,000,000 2.75% Convertible Senior Notes Due 2021 UNDERWRITING AGREEMENT Dated: November 16, 2016 PDL BIOPHARMA, INC. (a Delaware... (Filed With SEC on November 22, 2016)
- Noden Pharma DAC Investment and Stockholders Agreement (Filed With SEC on August 4, 2016)
- Schedule of Amendment to Omitted Credit Agreement (Filed With SEC on August 4, 2016)
- ASSET PURCHASE AGREEMENT (Tekturna, Rasilez) between NOVARTIS AG, NOVARTIS PHARMA AG, SPEEDEL HOLDING AG, AND NODEN PHARMA DAC... (Filed With SEC on August 3, 2016)
- Schedule of Amendment to Omitted Credit Agreements (Filed With SEC on February 23, 2016)
- Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked * * * and has been filed separately with the Securities and Exchange Commission pursuant... (Filed With SEC on November 4, 2015)
- Schedule of Amendment to Omitted Credit Agreement (Filed With SEC on February 23, 2015)
- EXCHANGE AGREEMENT (Unrestricted Stock) (Filed With SEC on February 23, 2015)
- THIRD AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT (Filed With SEC on February 23, 2015)
- SECOND AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT (Filed With SEC on February 23, 2015)
- FIRST AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT (Filed With SEC on August 18, 2014)
- NOTE PURCHASE AGREEMENT dated April 1, 2014 between ACCEL 300, LLC and THE PURCHASER NAMED HEREIN NOTES DUE JUNE 1, 2029 (Filed With SEC on August 18, 2014)
- ROYALTY PURCHASE AND SALE AGREEMENT dated as of October 18, 2013 between DEPOMED, INC., DEPO DR SUB, LLC, as Seller, and PDL BIOPHARMA, INC., as Purchaser (Filed With SEC on March 3, 2014)
- Form of Credit Agreement (Filed With SEC on March 3, 2014)
- SECOND SUPPLEMENTAL INDENTURE dated as of February 28, 2014 among PDL BIOPHARMA, INC., as Issuer, and THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A., as Trustee... (Filed With SEC on March 3, 2014)
- PDL BIOPHARMA, INC. asIssuer AND THEBANK OF NEW YORK MELLON TRUST COMPANY, N.A. as Trustee SUPPLEMENTAL INDENTURE Dated as of February 12, 2014 $300,000,000 4.00%... (Filed With SEC on February 12, 2014)
- PDL BIOPHARMA, INC. Debt Securities Indenture Dated as of February 12, 2014 The Bank of New York Mellon Trust Company, N.A., as Trustee CROSS-REFERENCE TABLE This Cross-Reference... (Filed With SEC on February 12, 2014)
- PDL BIOPHARMA, INC. (a Delaware corporation) $260,870,000 4.00% ConvertibleSenior Notes Due 2018 UNDERWRITING AGREEMENT Dated: February 6, 2014 PDL BIOPHARMA, INC. (a Delaware... (Filed With SEC on February 12, 2014)
- CREDIT AGREEMENT dated as of April 18, 2013 among AVINGER, INC. as the Borrower, PDL BIOPHARMA, INC., as the Lender, and PDL BIOPHARMA, INC., as the Agent (Filed With SEC on August 8, 2013)
- CREDIT AGREEMENT (Filed With SEC on August 2, 2012)
